Enanta Pharmaceuticals | ENTA - Interest Expense On Debt


Enanta Pharmaceuticals reported $1.96M in Interest Expense on Debt for its fiscal quarter ending in December of 2024.





Interest Expense On Debt Change Date
AbbVie USD 740M 40M Jun/2025
Amgen USD 653M 32M Dec/2025
Anika Therapeutics 189.44M 1.76M Sep/2025
Arrowhead Research USD 22.5M 811K Dec/2025
AstraZeneca USD 484M 181M Dec/2025
BioCryst Pharmaceuticals USD 24.45M 381K Dec/2024
Biogen USD 72.6M 12.6M Jun/2025
Bristol-Myers Squibb USD 432M 48M Dec/2025
Enanta Pharmaceuticals USD 1.96M 620K Dec/2024
Gilead Sciences USD 255M 1000K Dec/2025
GlaxoSmithKline GBP 188M 21M Dec/2025
Halozyme Therapeutics USD 4.91M 615K Dec/2025
Heron Therapeutics USD 500K 900K Sep/2024
Immunic 400K 400K Dec/2024
Incyte USD 582K 10K Dec/2025
Insmed USD 20.6M 217K Dec/2025
Ionis Pharmaceuticals USD 18M 0 Dec/2025
J&J USD 18M 290M Sep/2025
Karyopharm Therapeutics USD 11.38M 2.43M Sep/2024
Ligand Pharmaceuticals USD 910K 243K Sep/2025
Merck USD 412M 85M Dec/2025
Neurocrine Biosciences USD 1.1M 0 Mar/2024
Novartis USD 281M 8M Sep/2025
Novavax USD 4.24M 96K Sep/2024
Pfizer USD 711M 59M Dec/2025
PTC Therapeutics USD 50.58M 2.59B Dec/2025
Roche Holding CHF 304M 7.5M Jun/2025
Sarepta Therapeutics USD 7.56M 2.33M Sep/2025
Vertex Pharmaceuticals USD 3.3M 0 Dec/2025